Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Other Announcement

Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.

Ind-Swift Laboratories Capital Structure Change

Promoter entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants of Ind-Swift Laboratories via a preferential allotment.

Ind-Swift Laboratories Capital Structure Change

Ind-Swift Laboratories allotted 70 lakh fully convertible warrants at Rs. 196 each, totaling Rs. 137.2 Crore. This preferential issue will augment capital upon warrant conversion.

Value

₹137.2 Cr

Ind-Swift Laboratories Capital Structure Change

Ind-Swift Laboratories Limited allotted 70,00,000 fully convertible warrants to Essix Biosciences Limited on a preferential basis. The company received Rs. 34.30 Crore as upfront payment.

Value

₹34.30 Cr

Ind-Swift Laboratories Annual Report

Ind-Swift Laboratories has submitted its Annual Report for the financial year 2025-26. This filing provides the company's detailed financial performance and operational updates.

Ind-Swift Laboratories Annual General Meeting

Ind-Swift Laboratories Ltd will hold its 31st Annual General Meeting on September 30, 2026, via video conference. The agenda includes financial adoption and director appointments.

Ind-Swift Laboratories Capital Structure Change

Ind-Swift Laboratories' Preferential Issue Committee approved a revised issue price of Rs. 196 per warrant. The pricing follows SEBI ICDR regulations and a revised valuation report.

Ind-Swift Laboratories Management Change

Ind-Swift Laboratories Limited appointed Mr. Amit Mathur as a Non-Executive Independent Director, effective September 3, 2026. He brings over three decades of banking and financial expertise.

Ind-Swift Laboratories Board Meeting Outcome

Ind-Swift Laboratories appointed Mr. Amit Mathur as an Independent Director and scheduled its 31st AGM for September 30, 2026.

Ind-Swift Laboratories Investor Presentation: Key Takeaways

ISLL is transitioning from an API player to a pure-play Finished Dosage Formulation (FDF) manufacturer. Post-API business divestment, company is net debt-free with significant growth in EBITDA margins.

Call

Guides 50% growth

Ind-Swift Laboratories Q1 FY27 Results: Net Profit ₹24.7 Cr, Up 180.7% YoY

Ind-Swift Laboratories Ltd reported revenue from operations of ₹191.5 Cr (+21.0% YoY) and net profit of ₹24.7 Cr (+180.7% YoY) for Q1 FY27.

Key figure

Net profit ₹24.7 Cr · +180.7% YoY